Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the Parkinsonian brain

ACS Chemical Neuroscience

Volumn 4, Issue 5, 2013, Pages 680-692

  Navailles, S ^a,b   Lagieire M ^a,b   Contini, A ^a,b   De Deurwaerdeire P ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

Author keywords

5 HT neurons; clearance mechanisms; DA and 5 HT release; L DOPA; multisite intracerebral microdialysis; region dependent effects

Indexed keywords

DOPAMINE; LEVODOPA; SEROTONIN;

DOPAMINE RELEASE; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEEDBACK SYSTEM; HIPPOCAMPUS; INNERVATION; INTRACEREBRAL MICRODIALYSIS; MEDIAN RAPHE NUCLEUS; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR FUNCTION; SEROTONIN RELEASE; SUBSTANTIA NIGRA;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MICRODIALYSIS; NEOSTRIATUM; PARKINSON DISEASE; RATS; SEROTONERGIC NEURONS; SEROTONIN;

EID: 84877807553     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400046e     Document Type: Review

References (134)

1. Hornykiewicz, O. (1966) Dopamine (3-hydroxytyramine) and brain function Pharmacol. Rev. 18, 925-964
2. Cotzias, G. C., Papavasiliou, P. S., and Gellene, R. (1969) Modification of Parkinsonism - chronic treatment with L-dopa New Engl. J. Med. 280, 337-345
3. Di Chiara, G. (1990) In-vivo brain dialysis of neurotransmitters Trends Pharmacol. Sci. 11, 116-121
4. De Deurwaerdere, P. and Navailles, S. (2012) What can we expect from the serotonergic side of l-DOPA? Rev. Neurol. 168, 927-938
5. Ungerstedt, U. and Arbuthnott, G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24, 485-493
6. Lloyd, K. and Hornykiewicz, O. (1970) Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions Science 170, 1212-1213
7. Hefti, F., Melamed, E., and Wurtman, R. J. (1981) The site of dopamine formation in rat striatum after L-dopa administration J. Pharmacol. Exp. Ther. 217, 189-197
8. Melamed, E., Hefti, F., Liebman, J., Schlosberg, A. J., and Wurtman, R. J. (1980) Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease Nature 283, 772-774
9. Tison, F., Mons, N., Geffard, M., and Henry, P. (1991) The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain J. Neural Transm.: Parkinson's Dis. Dementia Sect. 3, 27-39
10. Nakamura, K., Ahmed, M., Barr, E., Leiden, J. M., and Kang, U. J. (2000) The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models Cell Transplant. 9, 567-576
11. Ng, K. Y., Chase, T. N., Colburn, R. W., and Kopin, I. J. (1970) L-Dopa-induced release of cerebral monoamines Science 170, 76-77
12. Gumpert, J., Sharpe, D., and Curzon, G. (1973) Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa J. Neurol. Sci. 19, 1-12
13. Korf, J., van Praag, H. M., Schut, D., Nienhuis, R. J., and Lakke, J. P. (1974) Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy Eur. Neurol. 12, 340-350
14. Hollister, A. S., Breese, G. R., and Mueller, R. A. (1979) Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity J. Pharmacol. Exp. Ther. 208, 37-43
15. Lopez, A., Munoz, A., Guerra, M. J., and Labandeira-Garcia, J. L. (2001) Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103, 639-651
16. Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol. Dis. 38, 136-143
17. Scheidtmann, K., Fries, W., Muller, F., and Koenig, E. (2001) Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study Lancet 358, 787-790
18. Rosser, N., Heuschmann, P., Wersching, H., Breitenstein, C., Knecht, S., and Floel, A. (2008) Levodopa improves procedural motor learning in chronic stroke patients Arch. Phys. Med. Rehabil. 89, 1633-1641
19. Ruscher, K., Kuric, E., and Wieloch, T. (2012) Levodopa treatment improves functional recovery after experimental stroke Stroke 43, 507-513
20. Abercrombie, E. D., Bonatz, A. E., and Zigmond, M. J. (1990) Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine- treated rats Brain Res. 525, 36-44
21. Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., and Cenci, M. A. (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112, 1465-1476
22. Maeda, T., Kannari, K., Suda, T., and Matsunaga, M. (1999) Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum Brain Res. 817, 185-191
23. Miller, D. W. and Abercrombie, E. D. (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats J. Neurochem. 72, 1516-1522
24. Kannari, K., Tanaka, H., Maeda, T., Tomiyama, M., Suda, T., and Matsunaga, M. (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation J. Neurochem. 74, 263-269
25. Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., and Matsunaga, M. (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats NeuroReport 10, 631-634
26. Arborelius, L., Nomikos, G. G., Grillner, P., Hertel, P., Hook, B. B., Hacksell, U., and Svensson, T. H. (1995) 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 157-165
27. Sprouse, J. S. and Aghajanian, G. K. (1987) Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists Synapse 1, 3-9
28. Temel, Y., Boothman, L. J., Blokland, A., Magill, P. J., Steinbusch, H. W., Visser-Vandewalle, V., and Sharp, T. (2007) Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus Proc. Natl. Acad. Sci. U.S.A. 104, 17087-17092
29. Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T., and Matsunaga, M. (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation J. Neurochem. 76, 1346-1353
30. Navailles, S. and De Deurwaerdere, P. (2010) Presynaptic control of serotonin on striatal dopamine function Psychopharmacology (Berlin, Ger.) 213, 213-242
31. Tan, S. K., Hartung, H., Visser-Vandewalle, V., Steinbusch, H. W., Temel, Y., and Sharp, T. (2012) A combined in vivo neurochemical and electrophysiological analysis of the effect of high-frequency stimulation of the subthalamic nucleus on 5-HT transmission Exp. Neurol. 233, 145-153
32. Yamato, H., Kannari, K., Shen, H., Suda, T., and Matsunaga, M. (2001) Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum NeuroReport 12, 1123-1126
33. Wachtel, S. R. and Abercrombie, E. D. (1994) L-3,4- dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors J. Neurochem. 63, 108-117
34. Bunney, B. S., Aghajanian, G. K., and Roth, R. H. (1973) Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones Nature (London), New Biol. 245, 123-125
35. Mercuri, N. B., Calabresi, P., and Bernardi, G. (1990) Responses of rat substantia nigra compacta neurones to L-DOPA Br. J. Pharmacol. 100, 257-260
36. Harden, D. G. and Grace, A. A. (1995) Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment J. Neurosci. 15, 6157-6166
37. Zigmond, M. J., Abercrombie, E. D., Berger, T. W., Grace, A. A., and Stricker, E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications Trends Neurosci. 13, 290-296
38. Azmitia, E. C. and Segal, M. (1978) An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat J. Comp. Neurol. 179, 641-667
39. Steinbusch, H. W. (1984) Serotonin-immunoreactive neurons and their projections in the CNS. In Handbook of Chemical Neuroanatomy-Classical transmitters and transmitters receptors in the CNS Part II (Björklund, A., Hökflet, T., and Kuhar, M. J., Eds.), pp 68-125, Elsevier: Amsterdam.
40. Mizoguchi, K., Yokoo, H., Yoshida, M., Tanaka, T., and Tanaka, M. (1993) Dopamine formation from L-dopa administered exogenously is independent of dopaminergic neuronal activity: studies with in vivo microdialysis Brain Res. 611, 152-154
41. Biggs, C. S. and Starr, M. S. (1997) Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra Neurosci. Biobehav. Rev. 21, 497-504
42. Thorre, K., Sarre, S., Smolders, I., Ebinger, G., and Michotte, Y. (1998) Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis Brain Res. 796, 107-116
43. Alam, M. R., Yoshizawa, F., and Sugahara, K. (2011) L-DOPA induced extracellular dopamine increases in the ventromedial hypothalamus affects food intake by chickens on a lysine-free diet Neurosci. Lett. 495, 126-129
44. Alam, M. R., Yoshizawa, F., and Sugahara, K. (2012) Local administration of L-DOPA in the chicken ventromedial hypothalamus increases dopamine release in a dose-dependent manner Neurosci. Lett. 529, 150-154
45. Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol. Dis. 41, 585-590
46. Seeman, P. (1980) Brain dopamine receptors Pharmacol. Rev. 32, 229-313
47. Hornykiewicz, O. (1973) Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA) Br. Med. Bull. 29, 172-178
48. Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temino, B., Mena-Segovia, J., Rodriguez, M., and Olanow, C. W. (2008) The basal ganglia in Parkinson's disease: current concepts and unexplained observations Ann. Neurol. 64 (Suppl 2) S30-46
49. Brown, W. D., Taylor, M. D., Roberts, A. D., Oakes, T. R., Schueller, M. J., Holden, J. E., Malischke, L. M., DeJesus, O. T., and Nickles, R. J. (1999) FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa Neurology 53, 1212-1218
50. Hery, F., Simonnet, G., Bourgoin, S., Soubrie, P., Artaud, F., Hamon, M., and Glowinski, J. (1979) Effect of nerve activity on the in vivo release of [3H]serotonin continuously formed from L-[3H]tryptophan in the caudate nucleus of the cat Brain Res. 169, 317-334
51. Melamed, E., Zoldan, J., Friedberg, G., Ziv, I., and Weizmann, A. (1996) Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy Adv. Neurol. 69, 545-550
52. Navailles, S., Carta, M., Guthrie, M., and De Deurwaerdere, P. (2011) L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease Cent. Nerv. Syst. Agents Med. Chem. 11, 305-320
53. Navailles, S. and De Deurwaerdere, P. (2012) Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia Parkinson's Dis. 2012, 323686
54. McQuade, R. and Sharp, T. (1997) Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis J. Neurochem. 69, 791-796
55. Blier, P., de Montigny, C., and ChaVput, Y. (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence J. Clin. Psychiatry 51 (Suppl) 14-20 discussion 21.
56. Hervas, I., Bel, N., Fernandez, A. G., Palacios, J. M., and Artigas, F. (1998) In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei Naunyn-Schmiedeberg's Arch. Pharmacol. 358, 315-322
57. Kreiss, D. S. and Lucki, I. (1994) Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei J. Pharmacol. Exp. Ther. 269, 1268-1279
58. Casanovas, J. M. and Artigas, F. (1996) Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways J. Neurochem. 67, 1945-1952
59. Casanovas, J. M., Lesourd, M., and Artigas, F. (1997) The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain B. J. Pharmacol. 122, 733-741
60. Invernizzi, R., Carli, M., Di Clemente, A., and Samanin, R. (1991) Administration of 8-hydroxy-2-(Di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity J. Neurochem. 56, 243-247
61. Romero, L. and Artigas, F. (1997) Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors J. Neurochem. 68, 2593-2603
62. van der Kooy, D. and Hattori, T. (1980) Bilaterally situated dorsal raphe cell bodies have only unilateral forebrain projections in rat Brain Res. 192, 550-554
63. Hopwood, S. E. and Stamford, J. A. (2001) Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphe nucle Neuropharmacology 40, 508-519
64. Moore, R. Y., Halaris, A. E., and Jones, B. E. (1978) Serotonin neurons of the midbrain raphe: ascending projections J. Comp. Neurol. 180, 417-438
65. Amilhon, B., Lepicard, E., Renoir, T., Mongeau, R., Popa, D., Poirel, O., Miot, S., Gras, C., Gardier, A. M., Gallego, J., Hamon, M., Lanfumey, L., Gasnier, B., Giros, B., and El Mestikawy, S. (2010) VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety J. Neurosci. 30, 2198-2210
66. Chung, E. K., Chen, L. W., Chan, Y. S., and Yung, K. K. (2006) Up-regulation in expression of vesicular glutamate transporter 3 in substantia nigra but not in striatum of 6-hydroxydopamine-lesioned rats Neurosignals 15, 238-248
67. Invernizzi, R., Velasco, C., Bramante, M., Longo, A., and Samanin, R. (1997) Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus Neuropharmacology 36, 467-473
68. Mazei, M. S., Pluto, C. P., Kirkbride, B., and Pehek, E. A. (2002) Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat Brain Res. 936, 58-67
69. Chotibut, T., Apple, D. M., Jefferis, R., and Salvatore, M. F. (2012) Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake PloS One 7, e52322
70. Carboni, E. and Silvagni, A. (2004) Dopamine reuptake by norepinephrine neurons: exception or rule? Crit. Rev. Neurobiol. 16, 121-128
71. Giros, B., Wang, Y. M., Suter, S., McLeskey, S. B., Pifl, C., and Caron, M. G. (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters J. Biol. Chem. 269, 15985-15988
72. Larsen, M. B., Sonders, M. S., Mortensen, O. V., Larson, G. A., Zahniser, N. R., and Amara, S. G. (2011) Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation J. Neurosci. 31, 6605-6615
73. Kannari, K., Shen, H., Arai, A., Tomiyama, M., and Baba, M. (2006) Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters Neurosci. Lett. 402, 62-65
74. Moron, J. A., Brockington, A., Wise, R. A., Rocha, B. A., and Hope, B. T. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines J. Neurosci. 22, 389-395
75. Aston-Jones, G., Zhu, Y., and Card, J. P. (2004) Numerous GABAergic afferents to locus ceruleus in the pericerulear dendritic zone: possible interneuronal pool J. Neurosci. 24, 2313-2321
76. Finberg, J. P., Wang, J., Bankiewicz, K., Harvey-White, J., Kopin, I. J., and Goldstein, D. S. (1998) Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1- aminoindan (rasagiline) in the monkey J. Neural Transm., Suppl. 52, 279-285
77. Sader-Mazbar, O., Loboda, Y., and Finberg, J. (2012) Role of the Organic Cation Transporter (OCT-3) and Monoamine Oxidase Types A and B in the Metabolism of Dopamine Derived from L-DOPA in Rat Striatum Depleted of Dopaminergic and Serotonergic Afferent Inputs. In The Tenth International Catecholamine Symposium, Asilomar, Pacific Grove, CA.
78. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 130, 1819-1833
79. Everett, G. M. and Borcherding, J. W. (1970) L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice Science 168, 847-850
80. Stansley, B. J. and Yamamoto, B. K. (2013) l-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells Neuropharmacology 67, 243-251
81. Berthet, A. and Bezard, E. (2009) Dopamine receptors and L-dopa-induced dyskinesia Parkinsonism Relat. Disord. 15 (Suppl 4) S8-12
82. Picconi, B., Ghiglieri, V., and Calabresi, P. (2010) L-3,4- dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias? Ann. Neurol. 68, 578-580
83. Picconi, B., Pisani, A., Barone, I., Bonsi, P., Centonze, D., Bernardi, G., and Calabresi, P. (2005) Pathological synaptic plasticity in the striatum: implications for Parkinson's disease Neurotoxicology 26, 779-783
84. Prescott, I. A., Dostrovsky, J. O., Moro, E., Hodaie, M., Lozano, A. M., and Hutchison, W. D. (2009) Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients Brain 132, 309-318
85. Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., and Cenci, M. A. (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann. Neurol. 68, 619-628
86. Zeng, B. Y., Iravani, M. M., Jackson, M. J., Rose, S., Parent, A., and Jenner, P. (2010) Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol. Dis. 40, 599-607
87. Lundblad, M., af Bjerken, S., Cenci, M. A., Pomerleau, F., Gerhardt, G. A., and Stromberg, I. (2009) Chronic intermittent L-DOPA treatment induces changes in dopamine release J. Neurochem. 108, 998-1008
88. Nevalainen, N., Af Bjerken, S., Lundblad, M., Gerhardt, G. A., and Stromberg, I. (2011) Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia J. Neurochem. 118, 12-23
89. Zahniser, N. R., Dickinson, S. D., and Gerhardt, G. A. (1998) High-speed chronoamperometric electrochemical measurements of dopamine clearance Methods Enzymol. 296, 708-719
90. Wang, Y. and Michael, A. C. (2012) Microdialysis probes alter presynaptic regulation of dopamine terminals in rat striatum J. Neurosci. methods 208, 34-39
91. Bungay, P. M., Newton-Vinson, P., Isele, W., Garris, P. A., and Justice, J. B. (2003) Microdialysis of dopamine interpreted with quantitative model incorporating probe implantation trauma J. Neurochem. 86, 932-946
92. Chen, K. C. (2005) Evidence on extracellular dopamine level in rat striatum: implications for the validity of quantitative microdialysis J. Neurochem. 92, 46-58
93. Bido, S., Marti, M., and Morari, M. (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels J. Neurochem. 118, 1043-1055
94. Mela, F., Marti, M., Bido, S., Cenci, M. A., and Morari, M. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels Neurobiol. Dis. 45, 573-582
95. Alexander, T., Sortwell, C. E., Sladek, C. D., Roth, R. H., and Steece-Collier, K. (1997) Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors Cell Transplant. 6, 309-315
96. Basma, A. N., Morris, E. J., Nicklas, W. J., and Geller, H. M. (1995) L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation J. Neurochem. 64, 825-832
97. Cheng, N., Maeda, T., Kume, T., Kaneko, S., Kochiyama, H., Akaike, A., Goshima, Y., and Misu, Y. (1996) Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons Brain Res. 743, 278-283
98. Pardo, B., Mena, M. A., and de Yebenes, J. G. (1995) L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells J. Neurochem. 64, 576-582
99. Hashiguti, H., Nakahara, D., Maruyama, W., Naoi, M., and Ikeda, T. (1993) Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis J. Neural Transm.: Gen. Sect. 93, 213-223
100. Eskow Jaunarajs, K. L., Angoa-Perez, M., Kuhn, D. M., and Bishop, C. (2011) Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment Neurosci. Biobehav. Rev. 35, 556-564
101. Kuhn, D. M. and Arthur, R., Jr. (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons J. Neurosci. 18, 7111-7117
102. Kuhn, D. M. and Arthur, R. E., Jr. (1999) L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein Brain Res. Mol. Brain Res. 73, 78-84
103. Eskow Jaunarajs, K. L., Dupre, K. B., Ostock, C. Y., Button, T., Deak, T., and Bishop, C. (2010) Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat Behav. Pharmacol. 21, 627-637
104. Maruyama, W., Naoi, M., Takahashi, A., Watanabe, H., Konagaya, Y., Mokuno, K., Hasegawa, S., and Nakahara, D. (1992) The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies J. Neural Transm.: Gen. Sect. 90, 183-197
105. Rascol, O., Brooks, D. J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., and Tolosa, E. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial Lancet 365, 947-954
106. Weinreb, O., Amit, T., Bar-Am, O., and Youdim, M. B. (2010) Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity Prog. Neurobiol. 92, 330-344
107. Carta, M., Carlsson, T., Munoz, A., Kirik, D., and Bjorklund, A. (2008) Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias Prog. Brain Res. 172, 465-478
108. Chase, T. N. (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 50, S17-25
109. de la Fuente-Fernandez, R., Sossi, V., Huang, Z., Furtado, S., Lu, J. Q., Calne, D. B., Ruth, T. J., and Stoessl, A. J. (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127, 2747-2754
110. Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Bjorklund, A., Bezard, E., and Carta, M. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain 131, 3380-3394
111. Ulusoy, A., Sahin, G., and Kirik, D. (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats Proc. Natl. Acad. Sci. U.S.A. 107, 13159-13164
112. Bishop, C., George, J. A., Buchta, W., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., Eissa, S., and Eskow Jaunarajs, K. L. (2012) Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats Eur. J. Neurosci. 36, 2839-2848
113. Durif, F., Vidailhet, M., Bonnet, A. M., Blin, J., and Agid, Y. (1995) Levodopa-induced dyskinesias are improved by fluoxetine Neurology 45, 1855-1858
114. Kuan, W. L., Zhao, J. W., and Barker, R. A. (2008) The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram Psychopharmacology (Berlin, Ger.) 197, 279-293
115. Cenci, M. A. and Lundblad, M. (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia J. Neurochem. 99, 381-392
116. Di Matteo, V., Di Giovanni, G., Pierucci, M., and Esposito, E. (2008) Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies Prog. Brain Res. 172, 7-44
117. Marin, C., Aguilar, E., Rodriguez-Oroz, M. C., Bartoszyk, G. D., and Obeso, J. A. (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats Psychopharmacology (Berlin, Ger.) 204, 241-250
118. Munoz, A., Carlsson, T., Tronci, E., Kirik, D., Bjorklund, A., and Carta, M. (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model Exp. Neurol. 219, 298-307
119. Orosz, D. and Bennett, J. P. (1992) Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the ″hemiparkinsonian″ rat Exp. Neurol. 115, 388-393
120. Sarre, S., Herregodts, P., Deleu, D., Devrieze, A., De Klippel, N., Ebinger, G., and Michotte, Y. (1992) Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study Naunyn-Schmiedeberg's Arch. Pharmacol. 346, 277-285
121. Sarre, S., Smolders, I., Thorre, K., Ebinger, G., and Michotte, Y. (1997) Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study J. Neural Transm. 104, 1215-1228
122. Eskow, K. L., Gupta, V., Alam, S., Park, J. Y., and Bishop, C. (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol., Biochem. Behav. 87, 306-314
123. Goetz, C. G., Damier, P., Hicking, C., Laska, E., Muller, T., Olanow, C. W., Rascol, O., and Russ, H. (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov. Disord. 22, 179-186
124. Gomez-Mancilla, B. and Bedard, P. J. (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys Clin. Neuropharmacol. 16, 418-427
125. Iravani, M. M., Tayarani-Binazir, K., Chu, W. B., Jackson, M. J., and Jenner, P. (2006) In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability J. Pharmacol. Exp. Ther. 319, 1225-1234
126. Kannari, K., Kurahashi, K., Tomiyama, M., Maeda, T., Arai, A., Baba, M., Suda, T., and Matsunaga, M. (2002) [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease] No To Shinkei 54, 133-137
127. Tomiyama, M., Kimura, T., Maeda, T., Kannari, K., Matsunaga, M., and Baba, M. (2005) A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease Neurosci. Res. 52, 185-194
128. Robertson, G. S. and Robertson, H. A. (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms J. Neurosci. 9, 3326-3331
129. Tucci, S., Fernandez, R., Baptista, T., Murzi, E., and Hernandez, L. (1994) Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats Brain Res. Bull. 35, 125-133
130. Mark, K. A., Soghomonian, J. J., and Yamamoto, B. K. (2004) High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity J. Neurosci. 24, 11449-11456
131. Morari, M., O'Connor, W. T., Darvelid, M., Ungerstedt, U., Bianchi, C., and Fuxe, K. (1996) Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium Neuroscience 72, 79-87
132. Del Arco, A. and Mora, F. (2009) Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders J. Neural Transm. 116, 941-952
133. Goto, Y. and Grace, A. A. (2008) Dopamine modulation of hippocampal-prefrontal cortical interaction drives memory-guided behavior Cereb. Cortex 18, 1407-1414
134. Nieoullon, A. (2002) Dopamine and the regulation of cognition and attention Prog. Neurobiol. 67, 53-83